These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 883553)

  • 21. Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity.
    Nowycky MC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Nov; 309(3):247-54. PubMed ID: 43476
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible role of brain serotonin and dopamine in controlling male sexual behavior.
    Gessa GL; Tagliamonte A
    Adv Biochem Psychopharmacol; 1974; 11(0):217-28. PubMed ID: 4276859
    [No Abstract]   [Full Text] [Related]  

  • 23. Gamma-type endorphins and brain dopaminergic systems.
    van Ree JM; Elands J; Kiraly I; Wolterink G
    Prog Clin Biol Res; 1990; 328():287-90. PubMed ID: 1968266
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of castration on dopamine receptor sensitivity in male young rats: behavioral and neurophysiological studies.
    Asakura W; Ohta H; Matsumoto K; Imamura L; Watanabe H; Matsuda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1994 Apr; 14(2):77-82. PubMed ID: 8042347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies.
    Martres MP; Costentin J; Baudry M; Marcais H; Protais P; Schwartz JC
    Brain Res; 1977 Nov; 136(2):319-37. PubMed ID: 922486
    [No Abstract]   [Full Text] [Related]  

  • 26. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
    Coward DM; Dixon AK; Urwyler S; White TG; Enz A; Karobath M; Shearman G
    J Pharmacol Exp Ther; 1990 Jan; 252(1):279-85. PubMed ID: 1967646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined treatment with dopaminergic and GABA-ergic drugs on the threshold for maximal electroconvulsions in mice.
    Czuczwar SJ
    Pol J Pharmacol Pharm; 1981; 33(1):25-35. PubMed ID: 6265890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-tolerance of dopamine metabolism to baclofen, gamma-butyrolactone and HA-966 in the striatum and olfactory tubercle of the rat.
    Broxterman HJ; Noach EL; van Valkenburg CF; Wijling A
    Life Sci; 1981 Mar; 28(9):973-81. PubMed ID: 7219068
    [No Abstract]   [Full Text] [Related]  

  • 29. Dopamine mediated behavior and GABA influence.
    Westerling P; Lindgren S; Höglund U
    Pharmacol Biochem Behav; 1988 Nov; 31(3):593-6. PubMed ID: 3251243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of dopamine-like compounds on stereotypy and locomotor activity in atropinized rats.
    Grabowska M
    Arch Immunol Ther Exp (Warsz); 1975; 23(6):753-61. PubMed ID: 1241267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of lesions of dopaminergic and serotonergic systems on apomorphine-induced hypothermia in the rat.
    Przewlocki R
    Pol J Pharmacol Pharm; 1977; 29(3):263-70. PubMed ID: 887502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat.
    Wallace TL; Gudelsky GA; Vorhees CV
    Synapse; 2001 Jan; 39(1):1-7. PubMed ID: 11071703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 10746B.
    Wood PL; Altar CA; Kim HS
    Life Sci; 1988; 42(16):1503-6. PubMed ID: 3352463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the action of (+/-)sulpiride on dopamine receptors in the rat brain in vivo.
    Hasan F; Leonard BE
    Neuropharmacology; 1981 Dec; 20(12B):1327-30. PubMed ID: 7198724
    [No Abstract]   [Full Text] [Related]  

  • 37. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone.
    Dyck LE; Kazakoff CW
    J Neurosci Res; 1982; 8(1):57-65. PubMed ID: 7175978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonstriatal dopaminergic neurons: Section VI. Action of dopamine at synaptic level:influence on postsynaptic cells: Introduction: action of dopamine at synaptic level: influence on postsynaptic cells.
    Iversen LL
    Adv Biochem Psychopharmacol; 1977; 16():381-3. PubMed ID: 883549
    [No Abstract]   [Full Text] [Related]  

  • 39. Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist.
    Dourish CT
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(1):3-27. PubMed ID: 6304814
    [No Abstract]   [Full Text] [Related]  

  • 40. Attenuation of the gamma-butyrolactone-induced increase in DOPA accumulation by chronic ethanol administration.
    Liljequist S; Engel J
    J Neural Transm; 1979; 46(3):195-204. PubMed ID: 528994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.